Intervet's bird flu vaccine receives EU license
Intervet, a leading animal health company, received
approval for its bird flu vaccine NobilisÂ® Influenza H7N1. Europe now has a
licensed vaccine to protect birds against the H7 field strain.
The vaccine protects against the different varieties of the highly
pathogenic H7 field strain. If embedded in national control programmes,
vaccination contributes substantially to controlling bird flu and reducing the
circulation of the bird flu
virus in the bird population, thereby reducing the
chance of human infection.
The vaccine contains inactivated virus, and has to be injected in order to
get a full immune response. Intervet
research is investigating the possibilities for a new
vaccine type for mass application avoiding injection.
To comment, login here
Or register to be able to comment.